Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6276177 | 0.86 | ALDH1A1 (0.53) | — | |
| SCHEMBL7146354 | 0.85 | ALDH1A1 (0.55) | — | |
| SCHEMBL72993 | 0.80 | PDE4B (0.60) | PDE4APDE4DPDE4BPDE4CMAPK14 | |
| SCHEMBL7322708 | 0.80 | PDE4B (0.60) | PDE4APDE4DPDE4BPDE4CMAPK14 | |
| SCHEMBL4825142 | 0.77 | PDE4B (0.55) | PDE4APDE4DPDE4BPDE4CMAPK14 | |
| SCHEMBL6283343 | 0.76 | PDE4B (0.57) | PDE4APDE4DPDE4BPDE4CMAPK14 | |
| SCHEMBL7332928 | 0.76 | PDE4D (0.79) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4825447 | 0.76 | PDE4B (0.56) | PDE4APDE4DPDE4BPDE4CMAPK14 | |
| SCHEMBL27472680 | 0.76 | PDE4D (0.68) | PDE4APDE4DPDE4BPDE4CMAPK14 | |
| SCHEMBL4818633 | 0.75 | PDE4A (0.72) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | PDE4A 355/4885PDE4D 611/4885PDE4B 433/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | PDE4A 568/4885PDE4D 1732/4885PDE4B 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.